Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02029469
Other study ID # CP- HRA-001
Secondary ID
Status Terminated
Phase N/A
First received April 25, 2012
Last updated August 15, 2014
Start date October 2007
Est. completion date July 2014

Study information

Verified date August 2014
Source Ascension Orthopedics, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

It is a non-randomized, consecutive enrollment, 10-year follow-up study of patients who are treated with the Ascension® HRA. Its purpose is to measure and document the outcomes associated with implanting the Ascension HRA prosthesis. Patients will be periodically assessed to collect data related to safety and effectiveness endpoints at the following intervals: preoperative, surgery/immediate post-op, 3 months, 6 months, 1 year, 2 year, 5 year, and 10 years.


Description:

At each assessment interval, information on complications and adverse events will be collected. In addition, shoulder joint range of motion will be collected, and implants will be evaluated radiographically to determine joint position and assess implant with regards to radiolucencies, subsidence and subluxation (migration). Patient satisfaction with regard to the effect of the implant on shoulder function, joint pain, and overall satisfaction will be assessed using a visual analog scale (VAS). Furthermore, if there are any implant revisions during the 10-year follow-up for any of the patients enrolled in the study, the implant and/or surrounding tissue will be harvested if possible and submitted for histopathological examination.


Recruitment information / eligibility

Status Terminated
Enrollment 59
Est. completion date July 2014
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- The following patient will be included in the study - Patient who:

- Is treated with the Ascension HRA;

- Is disabled by either non-inflammatory or inflammatory arthritis (i.e. rheumatoid arthritis, osteoarthritis and avascular necrosis;

- Has mild or moderate humeral head deformity and /or limited motion;

- Has post-traumatic arthritis;

- Has an intact or reparable rotator cuff;

- Has the means and ability to return for all required study visits

- Is willing to participate in the study;

- Has signed an Informed Consent Form;

- Is at least 18 years of age and skeletally mature at the time of surgery;

- Is less than 75 years of age at the time of surgery

Exclusion Criteria:

The following patients will be excluded from the study - Patients who:

- Infection, sepsis, and osteomyelitis;

- Osteoporosis;

- Metabolic disorders which may impair bone formation;

- Osteomalacia;

- Rapid joint destruction, marked bone loss or bone resorption apparent on X-ray;

- Revision procedures where other devices or treatments have failed

- Refuses to be in the study; or does not have the means and ability to return for all required study visits;

- Currently participating in another clinical study.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Ascension HRA device
Patients who are treated with the Ascension® HRA for resurfacing of humeral head.

Locations

Country Name City State
United States Bay Pines VA Healthcare System Bay Pines Florida

Sponsors (1)

Lead Sponsor Collaborator
Ascension Orthopedics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary American Shoulder and Elbow Surgeon Score The ASES score will be evaluated at 2 years and compared to baseline. Outcome data will be evaluated at 2 years No
Secondary Range of Motion Shoulder range of motion will be measured compared to baseline. 2 years No
Secondary VAS scale for pain VAS score for pain will be evaluated at 2 years and compared to baseline. 2 years No
Secondary AP and axillary radiographs Radiographs will be evaluated at 2 years for subsidence, lucent lines and evidence of movement or pending failure. 2 years Yes
Secondary Adverse events AEs will be assessed at each study timepoint 2 years and during entire trial Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05002335 - Clinical and Radiological Outcomes of Medacta Shoulder System (BE)
Recruiting NCT05868148 - Shoulder iDâ„¢ Primary Reversed Glenoid Outcomes Clinical Study
Recruiting NCT05926622 - Clinical and Radiological Outcomes of Medacta Shoulder System FR
Recruiting NCT03547947 - Clinical and Radiological Outcomes of Medacta Shoulder System
Recruiting NCT04968405 - Catalyst CSR Shoulder System for Semi or Total Shoulder Arthroplasty N/A
Active, not recruiting NCT05128500 - Follow-up Evaluating Clinical and Radiological Outcomes of Total Shoulder Arthroplasty With Permedica's MIRAI Prosthesis
Active, not recruiting NCT05002959 - TESS V3 Modular Total Shoulder System PMCF